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InsuTAG: A novel physiologically 
relevant predictor for insulin 
resistance and metabolic syndrome
Rohith N. Thota1, Kylie A. Abbott1, Jessica J. A. Ferguson1, Martin Veysey2, Mark Lucock3, 
Suzanne Niblett2, Katrina King  2 & Manohar L. Garg1
The aim of this study was to investigate whether a novel physiologically relevant marker, InsuTAG 
(fasting insulin × fasting triglycerides) can predict insulin resistance (IR) and metabolic syndrome 
(MetS). Data of 618 participants from the Retirement Health and Lifestyle Study (RHLS) were evaluated 
for the current study. IR was defined by homeostatic model assessment (HOMA-IR) scores. Pearson 
correlations were used to examine the associations of InsuTAG with HOMA-IR and other markers. 
Predictions of IR from InsuTAG were evaluated using multiple regression models. Receiver operating 
characteristic curves (ROC) were constructed to measure the sensitivity and specificity of InsuTAG 
values and to determine the optimum cut-off point for prediction of IR. InsuTAG was positively 
correlated with HOMA-IR (r = 0.86; p < 0.0001). InsuTAG is a strong predictor of IR accounting for 65.0% 
of the variation in HOMA-IR values after adjusting for potential confounders. Areas under the ROC curve 
showed that InsuTAG (0.93) has higher value than other known lipid markers for predicting IR, with 
a sensitivity and specificity of 84.15% and 86.88%. Prevalence of MetS was significantly (p < 0.0001) 
higher in subjects with InsuTAG values greater than optimal cut-off value of 11.2. Thus, InsuTAG 
appears to be a potential feasible marker of IR and metabolic syndrome.
The rise in sedentary lifestyle and ready access to calorie-dense processed foods in the modern-day world has 
created a convenient environment for the development of complex metabolic abnormalities in humans. Insulin, 
secreted by the pancreas, is one of the key anabolic hormones that tightly regulates glucose and lipid homeo-
stasis1. To maintain this homeostasis, insulin supresses hepatic glucose production, enhances glucose uptake 
in muscle and fat tissues, increases lipogenesis and regulates hepatic transport of very low-density lipoprotein 
(VLDL) associated triglycerides (TG)1. Chronic over-nutrition results in disruption of insulin signalling pathways 
leading to increased hepatic secretion of VLDL and possible decrease in the clearance of TG rich lipoproteins. 
As a result, levels of circulating TG are increased2, and this is commonly observed in insulin resistance (IR) 
and metabolic syndrome3. Insulin-mediated suppression of hepatic glucose production is still preserved in IR, 
however, suppression of VLDL-TG secretion is less pronounced4, indicating a rise in TG which may represent an 
early manifestation of IR. Cross-sectional studies5,6 and mechanistic studies7 have shown a positive association 
between circulating TG levels and both insulin sensitivity and action. Kriketos et al. 2003 has shown that both 
skeletal muscle TG and circulating TG were inversely associated with whole body insulin sensitivity7. Mingrone 
et al. 1997 showed reversibility of IR by lowering plasma TG in obese individuals with diabetes8; together these 
observations suggest that circulating TG may serve as a marker of IR and its associated complications.
Evidence of a relationship between TG and IR has escalated following the identification of “metabolic 
syndrome” (MetS), a condition representing a cluster of metabolic abnormalities with central obesity and IR 
postulated as core components9–11. A considerable body of evidence suggests that obesity-associated IR is an 
independent risk factor and a central component in the pathogenesis of type 2 diabetes and cardiovascular disease 
(CVD), both of which have reached epidemic proportions worldwide12,13. Evidence that IR causes type 2 diabetes 
comes from cross-sectional studies demonstrating the presence of IR in a majority of type 2 diabetes patients, 
and prospective studies demonstrating the development of IR long before the onset of type 2 diabetes14,15. 
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Dyslipidaemia associated with IR increases the risk of developing CVD in type 2 diabetes16,17. It is therefore 
important to quantify IR and identify MetS for primary and secondary prevention of these metabolic diseases.
Recognition of the importance of IR have prompted the derivation of a number of indices and surrogate 
markers to quantify IR18,19. Among these, the hyperinsulinemic euglycaemic clamp (HEC) technique has been 
described as the gold standard, providing a direct measure of IR20. However, cost, expertise, and the requirement 
for intravenous insulin infusions and frequent blood sampling limits the application of HEC in epidemiologi-
cal studies and routine clinical investigations. Homeostatic model assessment (HOMA) is a simple minimally 
invasive model that predicts IR using fasting steady-state glucose and insulin levels and that has been shown to 
be highly correlated with clamp insulin sensitive index values21. However, HOMA does not consider the level of 
blood lipids, such as TG or HDL-Cholesterol (HDL-C), despite lipid availability in circulation having an impor-
tant role in IR and its metabolic complications. In the current study we propose and evaluate a novel tool for 
estimating IR, InsuTAG. This model is based on the product of fasting blood insulin and fasting blood lipid (TG) 
levels. InsuTAG is unique in its incorporation of a measure of hyperinsulinemia and a measure of circulating TG 
in the general population, for identification of IR and its metabolic complications.
Results
After screening the 618 participants recruited for the RHLS study with exclusion criteria, 486 participants were 
included in the analysis. One hundred and thirteen participants were excluded because of self-reported dia-
betes. An additional 19 participants were excluded because they had blood glucose levels ≥7 mmol/L (n = 9); 
self-reported use of oral anti-hyperglycaemic agents (n = 4); had no blood glucose values recorded (n = 3); and/
or self-reported taking TG lowering medications (n = 3). Participant characteristics are outlined in Table 1. The 
study population was predominantly Caucasian (n = 469, 96.50%), included more females (n = 283, 58.23%) than 
males (n = 203, 41.77%), had a mean ± SD age of 77.78 ± 7.16 years, and a mean ± SD body mass index (BMI) 
of 28.05 ± 4.64 kg/m2. A total of 82 (16.87%) participants were categorised as IR according to HOMA-IR ≥2.5 
and 167 (37.03%) were identified as having MetS according to the International Diabetes Federation (IDF) cri-
teria. Fasting glucose, insulin, TG, weight, waist circumference (WC) and BMI were significantly (p < 0.0001) 
higher in individuals with IR compared with insulin-sensitive individuals (Table 1). InsuTAG scores ranged from 
0.55 to 132.07 across the whole participant group with a median (25th–75th percentile) InsuTAG score of 7.22 
(4.04–11.33)
There is a strong and highly significant positive correlation between InsuTAG and HOMA-IR (r = 0.86; 
p < 0.0001) (Fig. 1) when compared with the association between HOMA-IR and the other lipid indices, TyG 
index (triglycerides × glucose) (r = 0.43; p < 0.001) and TG/HDL-C ratio (r = 0.38; p < 0.001) (Table 2). InsuTAG 
is also positively associated with BMI (r = 0.51, p < 0.001) and WC (r = 0.48, p < 0.001).
Multiple regression analyses were used to evaluate the relationships between InsuTAG and other surrogate 
markers of IR with HOMA-IR (Table 3). Model 1 presents the unadjusted analyses. Model 2 present the anal-
yses adjusted for age, gender, WC and C-reactive protein (CRP). All surrogate markers of IR were significant 
predictors of HOMA-IR, both independently and after adjusting for covariates (p < 0.0001), however, InsuTAG 
accounted for a greater proportion of variability in HOMA-IR (Model 1, R2 = 0.739; Model 2, R2 = 0.738) than 
did the TyG index (Model 1, R2 = 0.183; Model 2, R2 = 0.303) or the TG/HDL-C ratio (Model 1, R2 = 0.145; 
Model 2, R2 = 0.284). Evaluation of the partial correlations indicated that, after adjusting for covariates, InsuTAG 
accounted for 65.0% of the variability in HOMA-IR scores, whereas TyG and TG/HDL-C were independently 
associated with only 7.9% and 5.4% of the change in HOMA-IR scores, respectively. Examination of the regres-
sion coefficient revealed that, after adjusting for covariates, a 10% increase in InsuTAG resulted in a correspond-
ing increase of 2.57% in HOMA-IR (p < 0.0001). In addition, logistic regression showed that after adjusting for 
age, gender, WC and CRP, each one-unit increase in InsuTAG increased the odds of having IR by 20% (OR 
(95%CI): 1.20 (1.15–1.26), p < 0.0001) and MetS by 16% (OR (95%CI): 1.16 (1.11–1.21), p < 0.0001).
ROC curves of InsuTAG and surrogate markers of IR were plotted to compare the predictive values for IR and 
MetS (Fig. 2). InsuTAG had significantly greater Area under the curve (AUC) values (AUC = 0.93, p < 0.001) than 
TyG index (AUC = 0.72) or TG/HDL-C (AUC = 0.70) for the identification of IR. For the identification of MetS, 
the AUC of InsuTAG (0.79) was significantly higher than HOMA-IR (0.73, p = 0.001) (Fig. 3), fasting insulin 
(0.69, p = 0.000) and WC (0.72, p = 0.009). The optimal cut off value for InsuTAG in identifying IR in the current 
study population was determined to be 11.2, with a sensitivity of 84.15% and specificity of 86.88%. At this cut-off, 
the sensitivity and specificity for MetS was 49.70% and 90.49% respectively (Table 4). Positive and negative pre-
dictive values along with likelihood ratios are also presented in Table 4. After determining the cut-off values 
for InsuTAG, the study population were categorised into two groups: InsuTAG < 11.2 (n = 364), and InsuTAG 
≥11.2 (n = 122). 74.34% of participants with InsuTAG values ≥11.2 were identified with MetS compared to only 
24.56% with InsuTAG values < 11.2 (Table 5, p < 0.0001). All the key components of the metabolic syndrome, 
WC (104.65 ± 12.45 vs 94.51 ± 11.79 cm); fasting glucose (5.46 ± 0.51 vs 5.14 ± 0.54 mmol/L); fasting TG [1.87 
(1.43–2.31) vs 1.01 (0.79–1.30) mmol/L]; and Total-C/HDL-C [3.60 (3.00–4.70) vs 2.90 (2.40–3.50)] were sig-
nificantly (p < 0.0001) higher in participants with InsuTAG values above the cut-off compared with participants 
InsuTAG values below the cut-off (Table 5). BMI, diastolic blood pressure, fasting insulin and HOMA-IR values 
were also significantly higher in the InsuTAG ≥11.2 group, whereas systolic blood pressure, glycosylated hae-
moglobin (HbA1c), total cholesterol and low density lipoprotein-cholesterol (LDL-C) did not differ between the 
two groups (Table 5). The lipid index values, TyG [10.29 (7.69–12.60) vs 5.25 (4.00–6.54)] and TG/HDL-C [1.41 
(1.07–1.91) vs 0.66 (0.48–0.89)] were almost doubled in participants with InsuTAG values above the cut-off.
Discussion
Many studies have evaluated lipid ratios, homeostatic models and individual metabolic variables for predicting 
IR6,22,23, however, none account for fasting insulin and fasting TG in a single model or formula. The current study 
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has evaluated the use of InsuTAG, a novel marker derived from the product of two key continuous variables, fast-
ing insulin and fasting TG, as a predictor for IR and metabolic abnormalities. InsuTAG demonstrated a stronger 
positive association (0.86) with HOMA-IR than the other individual metabolic markers and lipid surrogate mark-
ers analysed in this study. InsuTAG, TyG and TG/HDL-C were all independent predictors of IR in regression 
models; InsuTAG was the highest (65.0%) contributor to prediction of IR in the study population. ROC analysis 
also indicated InsuTAG (AUC 0.93) was the favourable marker over TyG index and TG/HDL-C for predicting IR.
HOMA-IR is the most common or frequently used index for assessing IR and closely mirrors HEC values24. 
Given that it is not feasible to conduct HEC in large study populations, in this study HOMA-IR scores of ≥2.5 
were used to identify IR. Previous studies proposed surrogate lipid-based markers such as TyG index and TG/
All Participants n = 486 Insulin Sensitive n = 404 Insulin Resistant n = 82 p-value
Gender (n, (%))
Male 203 (41.77) 172 (42.57) 31 (37.80) 0.425*
Female 283 (58.23) 232 (57.43) 51 (62.20) 0.425*
Age (years) 77.78 ±7.16 78.03 ±7.24 76.54 ±6.62 0.085
Waist Circumference (cm) 97.03 ±12.73 95.21 ±12.06 106.34 ±12.03 <0.0001
Height (m) 1.63 ±0.09 1.63 ±0.09 1.63 ±0.10 0.837
Weight (kg) 74.37 ±14.59 72.36 ±12.81 84.28 ±14.35 <0.0001
BMI (kg/m2) 28.05 ±4.64 27.29 ±4.36 31.76 ±4.18 <0.0001
Metabolic Syndrome† (n, (%)) 167 (37.03) 112 (29.55) 55 (76.39) <0.0001
Ethnicity (n, (%))
Caucasian 469 (96.50) 392 (97.03) 77 (93.90) 0.160‡
Aboriginal/Pacific Islander 6 (1.23) 5 (1.24) 1 (1.22) 0.998‡
Asian 1 (0.21) 0 (0.00) 1 (1.22) 0.026‡
Don’t know/didn’t respond 10 (2.06) 7 (1.73) 3 (3.66) 0.261‡
Dietary Energy Intake (Cal/day) 1971 ±725 1968 ±735 1983 ±679 0.865
Protein (g/day) 90.82 ±35.20 90.87 ±35.63 90.58 ±33.25 0.946
Fat (g/day) 68.95 ±31.87 69.42 ±32.89 66.67 ±26.46 0.478
Saturated fat (%Energy/day) 10.69 ±3.24 10.73 ±3.38 10.50 ±2.43 0.562
Fibre (g/day) 31.81 ±14.90 31.99 ±15.25 30.91 ±13.08 0.549
Physical Activity§ (n, (%))
High 120 (25.16) 108 (27.20) 12 (15.00) 0.020‡
Moderate 263 (55.14) 213 (53.65) 50 (62.50) 0.141‡
Low 74 (15.51) 62 (15.62) 12 (15.00) 0.888‡
Sedentary 20 (4.19) 14 (3.53) 6 (7.50) 0.102‡
Systolic Blood Pressure (mmHg) 145.99 ±20.90 146.00 ±21.68 145.94 ±15.99 0.984
Diastolic Blood Pressure (mmHg) 74.64 ±9.70 74.30 ±9.64 76.58 ±9.91 0.090
Fasting Glucose (mmol/L) 5.22 ±0.55 5.14 ±0.51 5.64 ±0.54 <0.0001
Fasting Insulin (μIU/L) 6.0 (4.0–8.6) 5.4 (3.8–7.2) 13.1 (12.0–16.8) <0.0001||
HbA1c (%) 5.72 ±0.34 5.70 ±0.31 5.85 ±0.44 0.0002
HbA1c (mmol/mol) 39 ±3.7 39 ±3.4 40 ±4.8 0.0002
Total Cholesterol (mmol/L) 4.69 ±1.02 4.72 ±1.01 4.57 ±1.08 0.241
Triglycerides (mmol/L) 1.15 (0.86–1.55) 1.10 (0.83–1.45) 1.54 (1.01–2.00) <0.0001||
LDL-C (mmol/L) 2.58 ±0.91 2.58 ±0.91 2.53 ±0.94 0.645
HDL-C (mmol/L) 1.49 (1.23–1.74) 1.53 (1.29–1.77) 1.25 (1.06–1.54)  < 0.0001||
Total-C/HDL-C 3.10 (2.50–3.80) 3.00 (2.50–3.70) 3.35 (2.80–4.30) 0.002
HOMA-IR 1.39 (0.90–2.06) 1.20 (0.84–1.69) 3.20 (2.87–4.04) <0.0001||
TyG 5.88 (4.46–8.12) 5.61 (4.13–7.47) 8.16 (5.88–11.12) <0.0001||
TG/HDL-C 0.77 (0.54–1.24) 0.72 (0.51–1.13) 1.18 (0.70–1.77) <0.0001||
Table 1. Participant characteristics of all participants and for participants stratified into subgroups by insulin 
resistance status. Data reported as count, mean ± SD or median (IQR, expressed as the 25th–75th percentile) 
unless otherwise specified. Insulin resistance categorised as HOMA-IR ≥2.5. Metabolic syndrome categorised 
according to IDF criteria. Difference between groups (Insulin Sensitive versus Insulin Resistant) assessed 
using two-tailed independent sample t-tests unless otherwise specified. *Categorical data assessed using chi-
squared analysis. †Incomplete data for metabolic syndrome for 35 participants (Insulin sensitive: n = 25; Insulin 
resistant: n = 10). ‡Differences assessed using a two-sample test of proportion. §Incomplete data for physical 
activity for 9 participants (Insulin sensitive: n = 7; Insulin resistant: n = 2). ||Non-parametric data assessed using 
Mann-Whitney U test. BMI: body mass index. Total-C/HDL-C: Total cholesterol/HDL-cholesterol. HOMA-IR: 
Homeostatic model assessment for Insulin Resistance. TyG: Triglycerides × glucose. TG/HDL-C: Triglycerides/
HDL-cholesterol.
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HDL-C ratio as an alternate approach to predict IR6,25. Consistent with previous reports22,26,27, the current study 
found significant and positive associations between HOMA-IR and BMI, WC and lipid ratios. InsuTAG demon-
strated a strong positive association with HOMA-IR, representing a close association with IR, higher than that 
of other lipid-based surrogate markers and anthropometric measurements analysed in this study population. 
Multivariate regression analysis indicated that both TyG index and TG/HDL-C were independent predictors 
for IR, findings that are consistent with previous published studies7,22. Amongst these independent predictors, 
InsuTAG accounted for the greatest variance in IR for this study population, accounting for 73.9% (without 
adjusting for covariates) and 65% (after adjusting for covariates) of variance in HOMA-IR. Along with the benefit 
of accounting for two key factors involved in the development of IR, these results indicate that InsuTAG may be 
a reliable and physiologically relevant marker for IR that can be easily calculated from routine clinical investiga-
tions. However, as HOMA-IR is not a gold standard method of determining IR, further validation studies of the 
predictive capacity of InsuTAG using clamp study insulin sensitivity index values are required.
AUC values from the ROC analysis showed that InsuTAG represented 93% probability of identifying indi-
viduals with IR in this study population, comparatively greater than the AUC’s of other lipid markers. The high 
sensitivity and specificity values of InsuTAG and positive likelihood ratio of 6.41 (Table 4) provides reasonable 
justification to explore InsuTAG as a diagnostic tool for IR. ROC analysis identified 11.2 as the optimal cut-off 
value for predicting IR in this study population. The corresponding value for identification of MetS was 8.0. The 
AUC for InsuTAG (0.79) suggests it is higher to HOMA-IR (0.73), fasting insulin (0.69) and WC (0.72) for pre-
dicting MetS in this study population. Metabolic characteristics of participants with InsuTAG scores above and 
below the suggested cut-off were compared. Significant differences in WC, BMI, fasting glucose, fasting insulin, 
TG, HDL-C and blood pressure, all of which are key components of MetS, were observed. There was no signif-
icant difference in participant characteristics between sub-groups stratified by the InsuTAG cut-off values for 
predicting IR (11.2) and MetS (8.0), other than minor changes in sensitivity and specificity values for MetS. No 
Figure 1. Scatterplot of InsuTAG and HOMA-IR. InsuTAG and HOMA-IR both loge transformed. Solid black 
line: line of best fit. Grey shaded area: 95% confidence interval.
Age BMI WC CRP InsuTAG† HOMA-IR† T:HDLratio TyG† TG/HDL-C
Age (years) — −0.14** −0.08 −0.01 −0.10* −0.09* −0.15*** −0.07 −0.07
BMI (kg/m2) −0.14** — 0.79*** 0.24*** 0.51*** 0.50*** 0.21*** 0.35*** 0.35***
WC (cm) −0.08 0.79*** — 0.16*** 0.48*** 0.47*** 0.24*** 0.35*** 0.40***
CRP (mg/L) −0.01 0.24*** 0.16*** — 0.18*** 0.15*** 0.12** 0.12** 0.14**
InsuTAG† −0.10* 0.51*** 0.48*** 0.18*** — 0.86*** 0.47*** 0.79*** 0.75***
HOMA-IR† −0.09* 0.50*** 0.47*** 0.15*** 0.86*** — 0.23*** 0.43*** 0.38***
Total-C/HDL-C −0.15*** 0.21*** 0.24*** 0.12** 0.47*** 0.23*** — 0.58*** 0.73***
TyG† −0.07 0.35*** 0.35*** 0.12** 0.79*** 0.43*** 0.58*** — 0.91***
TG/HDL-C† −0.07 0.35*** 0.40*** 0.14** 0.75*** 0.38*** 0.73*** 0.91*** —
Table 2. Correlations between contributors to insulin resistance, InsuTAG, and other surrogate markers of 
insulin resistance. Pearson product-moment correlation coefficients are presented. †Data loge transformed 
prior to analysis. *p < 0.05, **p < 0.01, ***p < 0.001. BMI: Body Mass Index. WC: Waist Circumference. 
CRP: C-reactive protein. InsuTAG: Fasting insulin (μIU/L) × triglycerides (mmol/L). HOMA-IR: Fasting 
glucose (mmol/L) × insulin (μIU/L). Total-C/HDL-C: Total cholesterol (mmol/L)/HDL cholesterol (mmol/L). 
TyG: Fasting triglycerides (mmol/L) × glucose (mmol/L). TG/HDL-C: Fasting triglycerides (mmol/L)/HDL-
cholesterol (mmol/L).
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further conclusions on these associations can be made at this point warranting further exploration in prospective 
studies to determine whether InsuTAG alone can predict the development of MetS.
We do acknowledge some limitations to this study. The study population is older and predominantly 
Caucasian, limiting the generalisability of InsuTAG to younger people and other ethnicities. Since it is less feasible 
to conduct HEC in studies with larger sample sizes, InsuTAG values were compared with HOMA-IR values rather 
than insulin sensitivity index values from clamp studies. Additional exploration of InsuTAG using glucose clamp 
studies is required to further validate this marker. Furthermore, because of the cross-sectional design of this 
study, no causal relationships can be determined. Longitudinal studies are required to evaluate whether InsuTAG 
can predict development of IR and MetS.
Surrogate markers for IR are less invasive and closely mirror correlation with HEC for metabolic and CVD 
risk. A recently published paper (20) on correlation of surrogate indices with HEC, concluded that surrogate mark-
ers including fasting insulin provided the most information relating to IR, compared with other complex and 
invasive procedures. The combination of fasting insulin and an indicator of reduced lipid clearance could provide 
more reliable information on IR and metabolic abnormalities.
In conclusion, we have proposed and evaluated a novel marker for IR that accounts for both fasting insulin 
and TG. It is simple to calculate and feasible for large cohort studies. This study substantiates and shows InsuTAG 
as a predictor of IR and a predictor of metabolic syndrome with higher sensitivity and specify values over other 
anthropometry and existing lipid surrogate indices. Further research is required to validate InsuTAG against HEC 
and determine whether it can accurately predict the development of IR and MetS in prospective studies.
Methods
This study is a sub-study of the Retirement Health and Lifestyle (RHLS), a cross-sectional study of Australians 
aged 65 years and older, living in the Central Coast of New South Wales, Australia. Inclusion and exclusion cri-
teria for participants in RHLS study has been described in detail elsewhere28,29. In brief, participants were invited 
to participate in the RHLS if they were: aged between 65 years or over; living in the Wyong Shire or Gosford City 
local government areas and living independently in retirement villages or within the community. Participants 
were included in the present study if: their diabetic status could be determined; their plasma fasting glucose, 
insulin and TG levels were available; and if they were not taking any TG-lowering medication. Participants pro-
vided written informed consent and ethics approval for this study was obtained from the University of Newcastle 
Human Research Ethics Committee (reference no. H-2008-0431) and the Northern Sydney Central Coast Health 
Human Research Ethics Committee (reference no. 1001–031 M). All testing was performed in accordance with 
the approved guidelines.
Demographic information, medical history, and information relating to medication and supplement intake 
were obtained from participants via interviewer-administered and self-administered questionnaire. Height 
and weight of study participants were measured using a portable stadiometer (design no. 1013522 Surgical and 
Medical products) and digital scales (Tanita HD 316 or Wedderburn UWPM150). BMI was calculated using the 
Surrogate Markers of IR
Model 1 Model 2





β-coefficient p adj. R2 p Partial R2 Semi-Partial R2 adj. R2 p
InsuTAG 0.739 <0.0001 0.738 <0.0001
InsuTAG* 0.637 <0.0001 0.613 0.650 0.487 <0.0001
Age — — 0.0002 <0.0001 <0.0001 0.930
Gender — — −0.022 0.0009 0.0002 0.524
WC — — 0.003 0.0077 0.002 0.058
CRP — — 0.00005 <0.0001 <0.0001 0.988
TyG 0.183 <0.0001 0.303 <0.0001
TyG* 0.559 <0.0001 0.342 0.079 0.060 <0.0001
Age — — −0.003 0.002 0.001 0.406
Gender — — 0.176 0.022 0.016 0.001
WC — — 0.020 0.149 0.120 <0.0001
CRP — — 0.007 0.003 0.002 0.214
TG/HDL-C Ratio 0.145 <0.0001 0.284 <0.0001
TG/HDL-C* 0.380 <0.0001 0.217 0.054 0.041 <0.0001
Age — — −0.003 0.001 0.001 0.426
Gender — — 0.214 0.032 0.024 <0.0001
WC — — 0.021 0.157 0.132 <0.0001
CRP — — 0.006 0.003 0.002 0.260
Table 3. Regression Models for predicting Insulin Resistance (IR)*. *IR defined by HOMA-IR value, InsuTAG, 
TyG and TG/HDL-C loge transformed prior to analysis. Model 1: Unadjusted estimates. Model 2: Adjusted 
for age, gender, waist circumference, CRP. A 1% increase in InsuTAG corresponds with a 0.265% increase in 
HOMA-IR or a 10% increase in InsuTAG corresponds with an increase to HOMA-IR of 2.57%.
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standard formula [weight (kg)/height (m)2]. WC was measured with a non-elastic measuring tape at the midpoint 
between the iliac crest and coastal margin in the mid-auxiliary line. All anthropometric measurements were con-
ducted by trained research officers.
Information on dietary intake was obtained from study participants using a self-administered 
semi-quantitative food frequency questionnaire (FFQ) adapted from a validated Commonwealth Scientific and 
Industrial Research Organisation Human Nutrition FFQ30. Diet, energy and nutrient intake information was 
analysed using Food Works Professional (2009 edition, version 6.0.2562, Xyris software, Brisbane, Australia) 
Figure 2. Receiver operating characteristic (ROC) curves for identifying Insulin Resistance (IR) using 
surrogate markers of IR. IR categorised as HOMA-IR ≥2.5. ROC curve for InsuTAG (a); ROC curve for TyG 
(b); ROC curve for TG/HDL-C (c). AUC: Area under the curve.
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in association with the following databases; Australia (fatty acids), Abbott products, AusFoods (brand) 2006, 
AusNut (all foods) 2007, and the New Zealand Vitamin and Mineral Supplement 1999.
Physical activity was assessed during the interviewer-administered questionnaire using questions designed to 
capture the frequency, duration and intensity of physical activity undertaken during the previous seven days. The 
questions were adapted from validated questionnaires measuring physical activity, and captured both incidental 
(e.g. household chores, gardening) and intentional (e.g. recreational sports, strength training) physical activity. 
Blood pressure measurements were taken with an OMRON 1A2 digital automatic blood pressure monitor in 
accordance with the “Measuring Blood Pressure” protocol published by the National Heart Foundation in 2008.
Figure 3. Receiver operating characteristic (ROC) curves for identifying Metabolic Syndrome (MetS) using 
InsuTAG and HOMA-IR. MetS categorised according to IDF criteria. ROC curve for InsuTAG(a); ROC curve 
for HOMA-IR (b). AUC: Area under the curve.
Sensitivity Specificity PV+ PV− LR+ LR−
Insulin Resistance 84.15% 86.88% 0.56 0.96 6.41 0.18
Metabolic Syndrome 49.70% 90.49% 0.75 0.75 5.23 0.56
Table 4. Predictive values of proposed InsuTAG cut-off of 11.2 for the identification of Insulin Resistance and 
Metabolic Syndrome. Insulin resistance classified according to HOMA-IR ≥2.5. Metabolic Syndrome classified 
according to IDF criteria. PV+: Positive predictive value. PV−: Negative predictive value. LR+: Positive 
likelihood ratio. LR−: Negative likelihood ratio.
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Blood samples were collected by trained phlebotomists following an overnight fast of at least 10 hours. Blood 
glucose control related parameters [fasting glucose (mmol/L), fasting insulin (mIU/L) and HbA1c], lipid pro-
file [TG, total cholesterol, LDL-C and HDL-C; mmol/L] and CRP (mg/mol) were analysed by Hunter Area 
Pathology Service using standard laboratory procedures. Fasting insulin and glucose were used to measure IR 
using HOMA-IR scores (fasting insulin × fasting glucose/22.5). Study participants with HOMA-IR values ≥2.5 
were categorised as insulin resistant. TyG index (fasting glucose × fasting TG) and TG/HDL-C ratio were also 
assessed. InsuTAG was calculated by multiplying fasting insulin (mU/L) and fasting TG (mmol/L). Participants 
were categorised as having MetS according to IDF criteria for abdominal obesity (waist circumference ≥94 cm 
for males, or ≥80 cm for females) plus any two of the following conditions (or self-report of receiving treatment 
for any of those conditions): high TG (≥1.7 mmol/L); high fasting glucose (≥5.6 mmol/L); high BP (≥130 mmHg 
systolic or ≥85 mmHg diastolic); and/or low HDL-C (<1.03 mmol/L for males, <1. 29 mmol/L for females).
The data of all variables included in the analysis were tested for normality using histograms and Shapiro-Wilk’s 
tests and are presented as mean ± SD or median (IQR) as appropriate. Heavily skewed parameters were 
log-transformed (log base e) prior to correlation and regression analyses. Distributions were reassessed after 
transformation and in all instances the log transformation successfully achieved a normal distribution. Bivariate 
relationships between continuous variables were assessed using Pearson’s Product-moment correlation. Standard 
InsuTAG < 11.2 n = 364 InsuTAG ≥11.2 n = 122 p-value
Gender (n, (%))
Male 153 (42.03) 50 (40.98) 0.839*
Female 211 (57.97) 72 (59.02) 0.839*
Age (years) 78.18 ±7.20 76.57 ±6.94 0.031
Waist Circumference (cm) 94.51 ±11.79 104.65 ±12.45 <0.0001
Height (m) 1.63 ±0.09 1.62 ±0.10 0.762
Weight (kg) 71.62 ±13.43 82.57 ±14.87 <0.0001
BMI (kg/m2) 26.96 ±4.21 31.25 ±4.36 <0.0001
Metabolic Syndrome† (n, (%)) 84 (24.56) 83 (74.34) <0.0001*
Dietary Energy Intake (Cal/day) 1959 ±732 2008 ±705 0.516
Protein (g/day) 90.98 ±36.30 90.36 ±31.80 0.868
Fat (g/day) 68.89 ±32.59 69.10 ±29.75 0.951
Saturated Fat (%Energy/day) 10.73 ±3.41 10.59 ±2.68 0.671
Fibre (g/day) 31.68 ±14.80 32.18 ±15.22 0.749
Physical Activity‡ (n, (%))
High 95 (26.61) 25 (20.83) 0.203§
Moderate 194 (54.34) 69 (57.50) 0.544§
Low 55 (15.41) 19 (15.83) 0.912§
Sedentary 13 (3.64) 7 (5.83) 0.269§
Systolic Blood Pressure (mmHg) 145.22 ±21.25 148.49 ±19.63 0.183
Diastolic Blood Pressure (mmHg) 74.03 ±9.77 76.64 ±9.26 0.021
Fasting Glucose (mmol/L) 5.14 ±0.54 5.46 ±0.51 <0.0001
Fasting Insulin (μIU/L) 5.0 (3.7–6.9) 11.3 (8.5–14.4) <0.0001||
HbA1c (%) 5.71 ±0.32 5.76 ±0.39 0.213
HbA1c (mmol/mol) 39 ±3.20 39 ±4.30 0.213
Total Cholesterol (mmol/L) 4.66 ±1.00 4.78 ±1.07 0.269
Triglycerides (mmol/L) 1.01 (0.79–1.30) 1.87 (1.43–2.31) <0.0001||
LDL-C (mmol/L) 2.56 ±0.89 2.63 ±0.97 0.443
HDL-C (mmol/L) 1.57 (1.32–1.82) 1.26 (1.08–1.52) <0.0001||
Total-C/HDL-C 2.90 (2.40–3.50) 3.60 (3.00–4.70) <0.0001
HOMA-IR 1.15 (0.82–1.62) 2.67 (2.05–3.55) <0.0001||
TyG 5.25 (4.00–6.54) 10.29 (7.69–12.60) <0.0001||
TG/HDL-C 0.66 (0.48–0.89) 1.41 (1.07–1.91) <0.0001||
Table 5. Participant characteristics and metabolic parameters of participants stratified into subgroups 
according to the proposed InsuTAG cut-off of 11.2. Data presented as mean ± SD or median (IQR, expressed as 
the 25th–75th percentile) unless otherwise specified. Metabolic Syndrome categorised according to IDF criteria. 
Differences between groups (InsuTAG <11.2 versus InsuTAG ≥11.2) assessed using two-tailed independent 
sample t-test unless otherwise specified. *Differences assessed using chi-squared analysis. †Incomplete data for 
metabolic syndrome for 35 participants (InsuTAG <11.2: n = 26; InsuTAG ≥11.2: n = 9). ‡Incomplete data for 
physical activity for 9 participants (InsuTAG <11.2: n = 7; InsuTAG ≥11.2 n = 2). §Differences assessed using 
a two-sample test of proportion. ||Non-parametric data assessed using Mann-Whitney U test. BMI: body mass 
index. Total-C/HDL-C: Total cholesterol/HDL-cholesterol. HOMA-IR: Homeostatic model assessment for 
Insulin Resistance. TyG: Triglycerides × glucose. TG/HDL-C: Triglycerides/HDL-cholesterol.
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multiple regression was used to assess the relationship of HOMA-IR with InsuTAG and other surrogate mark-
ers of IR, with and without adjustment for the potentially confounding variables: age, gender, WC and blood 
levels of CRP. Logistic regression was used to determine whether an increase in InsuTAG score was associated 
with increased odds of having IR or MetS. Receiver operating characteristic (ROC) curves were constructed for 
InsuTAG and other surrogate markers of IR to assess whether they were effective in identifying either IR and/
or MetS. For each marker, the area under the curve (AUC) was compared against HOMA-IR using the Stata 
command roccomp. Youden’s index was used to determine the optimum cut-off point, the point which has the 
greatest sensitivity and specificity, Participants were categorised according to whether their InsuTAG scores fell 
below or above the suggested cut-off point. Group differences were assessed using independent sample t-tests, 
Mann-Whitney U tests, or chi-squared analysis as appropriate. Significance was set at p < 0.05. All statistical 
analyses were conducted using Stata version 14.1 (StataCorp, Texas, USA).
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